Why the study?
The association between subclinical atherosclerosis and MAFLD or NAFLD, and the synergistic effect of DM and MAFLD on subclinical atherosclerosis, remained to be investigated.
Does metabolic dysfunction-associated fatty liver disease (MAFLD) and its combination with diabetes mellitus associate with increased subclinical atherosclerosis in a general health checkup population?
Population
890 subjects undergoing health checkups with CAC, carotid intima-media thickness, and ba-PWV
Comparison
MAFLD vs NAFLD vs Neither-FLD, and MAFLD subgroups (Obesity-MAFLD, Lean-MAFLD, DM-MAFLD)
Design
Cross-sectional study
Authors
Loading...
DM-MAFLD was associated with higher CAC>100 odds; hypothesis-generating for atherosclerosis risk stratification pending prospective validation.
Does metabolic dysfunction-associated fatty liver disease (MAFLD) and its combination with diabetes mellitus associate with increased subclinical atherosclerosis in a general health checkup population?
MAFLD, particularly when combined with diabetes mellitus, is significantly associated with a higher risk of subclinical atherosclerosis compared to NAFLD or the absence of fatty liver disease.
Bessho et al. (2022) studied this question.